Highlights Nektar Therapeutics

Equities

NKTR

US6402681083

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
1.5 ^USD	-9.09%		+2.74%	+165.49%

Apr. 24	Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases	CI
Mar. 19	Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases	Apr. 24	CI
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	Mar. 05	CI
Nektar Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q4 Revenue $23.9M, vs. Street Est of $21.4M	Mar. 04	MT
Nektar Therapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 04	CI
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q3 Revenue $24.1M, vs. Street Est of $21.3M	Nov. 07	MT
Nektar Therapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Nektar Therapeutics Presents New Responder Data for Rezpegaldesleukin, A First-In-Class Selective Regulatory T-Cell Therapy	23-10-13	CI
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer	23-09-27	CI
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-To-Severe Atopic Dermatitis	23-09-13	CI
Nektar Therapeutics Provides Earnings Guidance for the Year 2023	23-08-08	CI
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q2 Revenue $20.5M, vs. Street Est of $21.8M	23-08-08	MT
Nektar Therapeutics Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Nektar Therapeutics Sues Eli Lilly in California Over Autoimmune Disease Therapy Claims	23-08-07	MT
Nektar Therapeutics Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company	23-08-07	CI
Nektar Therapeutics Provides Earnings Guidance for the Year 2023	23-05-09	CI
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q1 Revenue $21.6M	23-05-09	MT
Nektar Therapeutics Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q4 Revenue $22M	23-02-28	MT
Nektar Therapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nektar Therapeutics

Equities

NKTR

US6402681083

Highlights

Filters